A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00676702
First received: May 8, 2008
Last updated: May 18, 2011
Last verified: February 2010
  Purpose

The purpose of the study is to evaluate the enzyme activity and safety of pancrelipase in patients with severe Exocrine Pancreatic Insufficiency (EPI)


Condition Intervention Phase
Exocrine Pancreatic Insufficiency
Pancreatitis, Chronic
Steatorrhea
Pancreatitis
Dietary Supplement: Ensure Plus
Drug: Pancrelipase in combination with Ensure Plus
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Official Title: A Single-Dose, Open-Label, Randomized, Crossover Study to Evaluate Intraduodenal Enzyme Delivery of PANCREASE MT in Subjects With Severe Exocrine Pancreatic Insufficiency

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • To evaluate the pharmacokinetics (enzyme activity) of intraduodenal enzyme (lipase, amylase, and protease) delivery of a single dose of 3 pancrelipase MT 21 capsules in gastric and duodenal fluid samples collected from patients [ Time Frame: Pretreatment and at 15 minute intervals up to 2 hours posttreatment on Day 1 during each treatment period. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of 3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase. [ Time Frame: Time of screening (Day -21) through to the end of the study procedures performed on Day 1 of treatment period 2. ] [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: July 2008
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
Drug: Pancrelipase in combination with Ensure Plus
3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
Active Comparator: 002
Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
Dietary Supplement: Ensure Plus
A high-fat liquid meal of 500 ml of Ensure Plus

  Hide Detailed Description

Detailed Description:

Pancrelipase, the active ingredient in pancrelipase microtablet (MT) 21 capsules, is a pancreatic enzyme preparation (PEP) for oral administration that aids in the digestion of fats, sugars and proteins. Approximately 20 men and women from 18 to 85 years of age will be enrolled in the study. Patients enrolled must have severe pancreatic insufficiency with steatorrhea (presence of fat in the stool as a result of insufficient fat absorption in the digestive track) due to severe exocrine pancreatic insufficiency (EPI), a condition when the body is unable to digest food because the body does not have digestive enzymes made by the pancreas to digest fats, sugars and proteins properly for normal nutritional needs. The study will last approximately 25 days and will consist of a screening phase that will take place within 21 days before an open-label (patient knows the identity of the treatment they are receiving) treatment phase that will consist of 2 treatment periods (each treatment period will be approximately 4 hours long), a 2-day washout period between treatment periods, and an end-of-study evaluation upon successful completion of the sample collection in treatment period 2. Study participants will arrive at the study center no later than 6 p.m. on the day before treatment period 1 and stay overnight at the study center until the end-of-study evaluation in treatment period 2 (approximately 5 days). During the study, patients may not consume food or beverages containing alcohol, must refrain from the use of any methylxanthine-containing products, (eg, chocolate bars or beverages, coffee, teas, or colas), must eat only the meals provided during the study while residing at the study center, and must refrain from jogging, strenuous exercise of all types, and sunbathing. At the screening visit, patients will be asked to sign an informed consent form indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Patients will then be asked to provide information regarding their medical history and will have a complete physical examination (including heart and respiration rate, blood pressure, temperature, height, and weight) performed. In addition, a blood sample (10 mL or approximately 2 teaspoons of blood) and a urine sample will be collected to assess the patient's general health. A urine pregnancy test will also be performed on women of childbearing age. If the patient is eligible to participate in the study, he/she will be asked to stop taking any existing pancreatic enzymes, prescription and nonprescription medications (including vitamins and herbal supplements) that could affect the stomach or intestines for 3 to 7 days before returning to the study center for treatment periods 1 and 2. During the study, patients will receive either Treatment A in Period 1 and Treatment B in Period 2; or Treatment B in Period 1 and Treatment A in Period 2. The day before (Day -1) of treatment period 1, patients will be randomly (by chance) assigned to 1 of 2 treatment sequences (Treatment A or Treatment B). Treatment A will consist only of a high-fat liquid meal (500 mL of Ensure Plus containing 22.9 g of fat). Treatment B will consist of 3 PANCREASE MT 21 capsules taken orally (by mouth) along with a high-fat liquid meal (500 mL of Ensure Plus containing 22.9 g of fat). Following an overnight fast (without eating) of at least 10 hours, patients will be intubated (ie, have a tube inserted through their nose into the small intestine [duodenum]) in order to collect samples of fluid from their stomach and intestine before and after treatment in treatment periods 1 and 2. In treatment period 1, patients will be given the study treatment (Treatment A or Treatment B) orally (by mouth) over a 20-25 minute period, followed by a 2-hour sample collection period. After the sample completion period, the intubation tube will be removed and patients will have a washout period of at least 48 hours where they will rest and not receive treatment. At the end of the washout period, patients will enter treatment period 2 and receive the second study treatment. Patient's may be required to stay overnight for observation after the completion of the sample collection in Period 2, otherwise, patients will be permitted to leave the study center on Day 1 of treatment period 2 following a physical examination and collection of blood and urine samples for safety assessments. The primary outcome in the study is to evaluate the pharmacokinetics (enzyme activity) of intraduodenal enzyme (lipase, amylase, and protease) delivery of a single dose of 3 pancrelipase MT 21 capsules in gastric and duodenal fluid samples collected from patients before treatment and at 15 minute intervals up to 2 hours after treatment on Day 1 during each treatment period. During the study, the safety and tolerability of study drug will be monitored from the time of screening (Day -21) through to the end of the study procedures performed on Day 1 of treatment period 2 by evaluating adverse events (side effects), results from clinical laboratory tests (serum chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and body temperature) measurements, and findings from physical examinations reported. Adverse events reported by patients were also monitored for up to 30 days following discharge from the study center. On Day 1 of the first treatment period, patients will receive Treatment A (a high-fat liquid meal of 500 ml of Ensure Plus) OR Treatment B (3 pancrelipase microtablet (MT) 21 capsules taken orally by mouth in addition to a high-fat liquid meal of 500 ml of Ensure Plus) ingested within 20-25 minutes. After a 2-day washout period, in the second treatment period, patients who received Treatment A in period 1 will receive Treatment B and patients who received Treatment B will receive Treatment A.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have evidence of chronic pancreatitis or pancreatic insufficiency (steatorrhea) confirmed prior to screening
  • Must be able to discontinue treatment with any pancreatic enzyme preparations (PEPs) within 72 hours before admission to the study center for the open-label phase to the end-of-study evaluations (a total of approximately 7 days)
  • If a woman, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study and have a negative urine pregnancy test at screening
  • Must have signed an informed consent document indicating an understanding of the purpose and procedures required for the study and willingness to participate in the study

Exclusion Criteria:

  • Current significant medical and/or mental disease including solid organ transplant, massive small bowel resection, or major gastrointestinal or pancreatic surgery that potentially affect the intestinal absorption and metabolism of fat (excluding severe pancreatic insufficiency with steatorrhea due to chronic pancreatitis or exocrine pancreatic insufficiency)
  • History of or current acute pancreatitis or acute exacerbations of chronic pancreatic disease, or coagulopathy
  • Use of any prescription that can influence gastrointestinal physiology or any nonprescription medication (including vitamins and herbal supplements) except for acetaminophen, oral contraceptives, and hormonal replacement therapy, and local numbing agents, short-acting benzodiazepines, metoclopramide used during the placement of the intubation tube for up to 3 to 7 days before admission to the study center
  • Known allergy to the study drug, pork protein, or any of the excipients of the pancreatic enzyme formulation or to medications used during the placement of the intubation tube (ie, local numbing agents, short-acting benzodiazepines, metoclopramide)
  • Unable to swallow solid, oral dosage forms whole with the aid of a liquid meal (participants may not chew, divide, dissolve, or crush the study drug) and/or tolerate gastroduodenal intubation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00676702

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Additional Information:
No publications provided

Responsible Party: Senior Director Clinical Research and Development, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00676702     History of Changes
Other Study ID Numbers: CR014716, PNCRLPCYS1001
Study First Received: May 8, 2008
Last Updated: May 18, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Pancrelipase
PANCREASE MT
Cross-Over Studies
Duodenum
Intestine, Small
Lipase
Amylases
Peptide Hydrolases
Intubation
Safety
Capsules

Additional relevant MeSH terms:
Exocrine Pancreatic Insufficiency
Pancreatitis
Steatorrhea
Pancreatitis, Chronic
Pancreatic Diseases
Digestive System Diseases
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Metabolic Diseases
Pancrelipase
Pancreatin
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014